<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032807</url>
  </required_header>
  <id_info>
    <org_study_id>IRAS: 288415</org_study_id>
    <nct_id>NCT05032807</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation</brief_title>
  <acronym>CLIP</acronym>
  <official_title>Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cannabidiol (CBD) has been approved as a treatment for rare childhood epilepsies and could be&#xD;
      an effective treatment for psychotic disorders, anxiety disorders and addictions. It is&#xD;
      available as an oral liquid and as standard oral capsules.&#xD;
&#xD;
      The bioavailability of oral cannabidiol is poor (only around 5-10% is absorbed), particularly&#xD;
      in the fasted state. With food, its absorption is much higher. In one study, a high-fat&#xD;
      breakfast increased the maximum plasma concentration by 4-5 times. As a result of this food&#xD;
      effect, when prescribing standard oral formulations of CBD, clinicians should provide advice&#xD;
      on dosing the drug according to mealtimes, otherwise, there may be an increased risk of side&#xD;
      effects or limited effectiveness.&#xD;
&#xD;
      One way to reduce the food effect and improve bioavailability is to use lipid encapsulation.&#xD;
      In the present study, the investigators will evaluate CBD at the dose that is effective in&#xD;
      patients with chronic psychosis (1000mg). The novel formulation will use lipids that are all&#xD;
      EU pharmacopoeia approved and have been used in medicinal products before.&#xD;
&#xD;
      The study aims to assess whether a novel lipid formulation can increase the bioavailability&#xD;
      of oral CBD in the fasting state.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total drug exposure. (Area under the curve to infinity [AUC(inf)]</measure>
    <time_frame>0 - 48 hours</time_frame>
    <description>Difference in AUC(inf) for a single dose of oral CBD between the novel and standard formulations in the fasting state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>0 - 48 hours</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>0 - 48 hours</time_frame>
    <description>Time after administration of drug when maximum plasma concentration is reached</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life (t½)</measure>
    <time_frame>0 - 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>48 hour drug exposure (AUC0-48)</measure>
    <time_frame>0 - 48 hours</time_frame>
    <description>Area under the concentration-time curve from time zero to 48hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Absorption; Chemicals</condition>
  <arm_group>
    <arm_group_label>Novel lipid formulation cannabidiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard formulation cannabidiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol standard formulation</intervention_name>
    <description>Cannabidiol 1000mg standard formulation, single dose, oral</description>
    <arm_group_label>Standard formulation cannabidiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol novel formulation</intervention_name>
    <description>Cannabidiol 1000mg with lipid encapsulation, single dose, oral</description>
    <arm_group_label>Novel lipid formulation cannabidiol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Healthy volunteers&#xD;
&#xD;
          -  Age 18-45&#xD;
&#xD;
          -  Females of childbearing potential and males must be willing to use highly effective&#xD;
             method of contraception (hormonal or barrier method of birth control; abstinence)&#xD;
             throughout the duration of the study and for at least 4 weeks after&#xD;
&#xD;
          -  Agreeing to fast 15 hours; 10pm-1pm on dosing days&#xD;
&#xD;
          -  Capable of giving informed consent&#xD;
&#xD;
          -  Written informed consent from participant&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Any prescribed medication (apart from contraceptives)&#xD;
&#xD;
          -  Use of any CBD products within the last six months&#xD;
&#xD;
          -  Use of any over-the-counter medications or health supplements within the past 2 weeks&#xD;
&#xD;
          -  BMI &lt;18 or &gt;30.0kg/m2&#xD;
&#xD;
          -  History of alcohol or substance misuse disorder&#xD;
&#xD;
          -  Smokes more than 10 cigarettes per day&#xD;
&#xD;
          -  Use of any illicit substances within the last six months&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  eGFR≤ 70 mls/min&#xD;
&#xD;
          -  Any liver function or renal function test abnormality&#xD;
&#xD;
          -  Urine drug screen positive for any substances&#xD;
&#xD;
          -  Positive alcohol breath test&#xD;
&#xD;
          -  Participant in any other clinical trial or experimental drug study in the past 3&#xD;
             months&#xD;
&#xD;
          -  Known hypersensitivity to CBD and/or SEEK formulation excipients&#xD;
&#xD;
          -  Participant is not able to swallow capsules&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Edward Chesney, BM BCh</last_name>
    <phone>07711887754</phone>
    <email>edward.chesney@kcl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <zip>SE5 8AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

